Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2020-04-17 AGM Information
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Attendance at the Company's annual general meeting
AGM Information Classification · 1% confidence The document explicitly discusses the arrangements for the company's 'annual general meeting ("AGM")' scheduled for April 23, 2020. It reminds shareholders about the formal business, discourages in-person attendance due to government advice, and provides instructions for proxy voting. It also mentions an alternative presentation via videoconference. Since the core subject is the logistics and updates surrounding the AGM, the most appropriate classification is AGM Information (AGM-R). Although it is distributed via RNS, the content is specific to the AGM proceedings, not a general regulatory announcement.
2020-04-17 English
Verona Pharma plc: Results of AGM
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly states that it announces that 'all resolutions proposed at the Annual General Meeting held today were duly approved by shareholders by way of a poll.' It further mentions that the 'results of the poll are available on the Investors section of the Company’s website.' This content directly relates to the outcome of a shareholder vote following an AGM. Therefore, the most appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). Although it mentions the AGM, the core content is the result announcement, not the AGM presentation itself (AGM-R) or the proxy materials (PSI). Given the short length and focus on announcing the result availability, DVA is the best fit.
2020-04-16 English
Covid-19 Project Update
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and explicitly states, 'This information is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 ("MAR").' It is a brief update regarding a Covid-19 project timeline and participation in a partnering event. The footer confirms it is provided by RNS, the news service of the London Stock Exchange, which acts as a Primary Information Provider. This structure strongly indicates a general regulatory announcement or news release, which fits the definition of Regulatory Filings (RNS) or potentially an Earnings Release (ER) if it contained financial results, but since it is a project update and uses the RNS format, RNS is the most appropriate general classification. It is not a full report (10-K, IR), a transcript (CT), or a specific financial event announcement (DIV, CAP).
2020-04-16 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1372 characters) and explicitly states it is an 'RNS Number' notification from the London Stock Exchange. The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a specific, immediate operational announcement rather than a comprehensive financial report (like 10-K or IR) or a standard management/shareholder communication. Since it is a general regulatory announcement provided via the RNS service and does not fit into the more specific categories (like DIV, DIRS, ER), the most appropriate classification is the general regulatory fallback category.
2020-04-15 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1355 characters) and begins with an 'RNS Number' and the issuer name, indicating it is a regulatory news service announcement from the London Stock Exchange. The content specifically discusses a 'Price Monitoring Extension' for a security, which is a routine operational update related to trading mechanisms. This type of miscellaneous, non-standard regulatory announcement that doesn't fit into specific financial reporting categories (like 10-K, ER, or DIV) is best classified under the general regulatory filing category, RNS (Regulatory Filings). It is not an Earnings Release, Audit Report, or a formal report announcement like RPA, but rather a direct regulatory notification.
2020-04-15 English
Update on AGM Procedure
Report Publication Announcement Classification · 1% confidence The document explicitly discusses the upcoming Annual General Meeting ("AGM"), providing details on the date, time, location, and instructions for shareholders regarding proxy voting due to public gathering restrictions. The core subject matter is the logistics and management of the AGM. This directly aligns with the definition for AGM Information (AGM-R). Although it mentions the Annual Report is available, the primary focus and purpose of this specific communication is the AGM update.
2020-04-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.